Join

Compare · DXCM vs SGHT

DXCM vs SGHT

Side-by-side comparison of DexCom Inc. (DXCM) and Sight Sciences Inc. (SGHT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both DXCM and SGHT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • DXCM is the larger of the two at $23.67B, about 97.8x SGHT ($242.1M).
  • Over the past year, DXCM is down 24.8% and SGHT is up 46.1% - SGHT leads by 70.9 points.
  • Both names hit the wire about 8 times in the past 4 weeks.
  • DXCM has more recent analyst coverage (25 ratings vs 19 for SGHT).
PerformanceDXCM-24.81%SGHT+46.05%
2025-05-02+0.00%2026-05-01
MetricDXCMSGHT
Company
DexCom Inc.
Sight Sciences Inc.
Price
$61.33+3.02%
$4.44+8.82%
Market cap
$23.67B
$242.1M
1M return
-1.65%
+21.15%
1Y return
-24.81%
+46.05%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NASDAQ
IPO
2005
2021
News (4w)
8
8
Recent ratings
25
19
DXCM

DexCom Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

SGHT

Sight Sciences Inc.

Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.